Six Trial Activations: Impressive Q1 for SWOG
Quarter 1 of 2023 has just closed, and SWOG has already activated six trials.
This is a remarkable testament to the hard work of our staff and the research productivity of our investigators. I extend my deepest thanks to everyone who has contributed to starting these studies, and to the development of numerous others now approaching the launch pad.
Here are introductions (or reintroductions) to the six new studies, most recent first:
S1900G: Lung-MAP sub-study in EGFR-mutant, MET-amplified NSCLC
PI: Sarah Goldberg, MD, MPH
The newest sub-study under our Lung Master Protocol, S1900G will enroll patients with advanced, EGFR-mutated non-small cell lung cancer that has progressed on osimertinib because of MET amplification. This study asks whether adding ramucirumab can help overcome acquired resistance to osimertinib in these patients.
S2205: ICE COMPRESS study of cooling and compression to prevent neuropathy
PI: Melissa K. Accordino, MD, MS
This trial testing strategies to prevent taxane-induced peripheral neuropathy compares cryocompression (using the Paxman limb cooling system) to continuous compression and to low cyclic compression. Open at 37 select sites, across all four adult NCTN groups, the trial aims to enroll almost 800 patients within about 30 months.
PI: Karen Reckamp, MD
I’ve discussed this study before in Front Line (more than once), so all I’ll say here is that it’s open, it has enrolled its first patients, and if you haven’t yet started to activate it at your site, you should certainly consider doing so.
EAY191-S3: ComboMATCH sub-study in AKT-altered tumors
PI: Reva Basho, MD
You may not immediately recognize this trial number as a SWOG study, but get ready to see new naming conventions, as MyeloMATCH and ImmunoMATCH will soon join ComboMATCH in breaking the molds. This first SWOG ComboMATCH sub-study tests adding ipatasertib to paclitaxel for patients with AKT-mutated non-breast solid tumors that have previously progressed on taxane-based therapy.
S2114: Post CAR T-cell consolidation for DLBCL and follicular lymphoma
PI: Brian T. Hess, MD
S2114 tests three options (plus observation) for consolidation therapy to improve outcomes for patients after CD19 CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma. If you have questions about this trial, be sure to attend the Friday morning S2114 kickoff session at group meeting next month to have them answered!
S2010: ASPEN study of active symptom monitoring with endocrine therapy
PI: N. Lynn Henry, MD, PhD
This randomized phase 3 trial adds active symptom monitoring between clinic visits to standard patient education efforts to learn whether it can help women with breast cancer stay on endocrine therapy longer and whether it can help reduce their treatment-associated symptoms. The study team is also developing a risk prediction model to identify which patients are likely to benefit from active symptom monitoring.
The good news doesn’t stop with our six trials already activated this year. SWOG has numerous other protocols in advanced stages of development, with another half-dozen activations expected in Q2 of 2023. Our banner year will continue!